The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 11, 2025

Filed:

Oct. 08, 2021
Applicant:

The Regents of the University of Colorado, a Body Corporate, Denver, CO (US);

Inventors:

Kenneth N. Maclean, Lakewood, CO (US);

Johan Van Hove, Castle Rock, CO (US);

Hua Jiang, Centennial, CO (US);

Michael A. Swanson, Denver, CO (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/19 (2006.01); A61K 31/145 (2006.01); A61K 31/198 (2006.01); A61K 31/205 (2006.01); A61K 31/4172 (2006.01); A61K 33/30 (2006.01); A61K 33/34 (2006.01); A61P 13/02 (2006.01);
U.S. Cl.
CPC ...
A61K 31/19 (2013.01); A61K 31/145 (2013.01); A61K 31/198 (2013.01); A61K 31/205 (2013.01); A61K 31/4172 (2013.01); A61K 33/30 (2013.01); A61K 33/34 (2013.01); A61P 13/02 (2018.01);
Abstract

Embodiments of the instant disclosure relate to novel compositions and methods for treating a subject having homocystinuria. In some embodiments, compositions and methods disclosed herein concern improving efficacy of betaine to reduce dietary compliance requirements and improve outcomes. In accordance with these embodiments, a subject having or suspected of developing homocystinuria can be treated with formate, a salt thereof, a formate derivative or formate precursor or prodrug agent alone or in combination with trimethylglycine or other HCU treatments. In other embodiments, a subject having or suspected of developing homocystinuria can be treated with zinc and/or trimethylglycine and/or formate derivative to treat homocystinuria in the subject. In other embodiments, a subject having or suspected of developing Nonketotic hyperglycinemia (NKH) can be treated with formate, a salt thereof, a formate derivative, or formate precursor or prodrug agent to treat NKH in the subject.


Find Patent Forward Citations

Loading…